PALO ALTO, California, April 30 /PRNewswire/ --

- Accomplished regulatory executive enhances Nfocus device development team.

Endovascular device start-up Nfocus Neuromedical Inc. announced today the appointment of accomplished regulatory executive Robert O'Holla to its leadership team in the role of Vice President of Regulatory Affairs.

Bob O'Holla brings an unmatched wealth of regulatory and compliance experience to Nfocus, having served 18 of his last 30 years in the industry in the role of Worldwide Vice President of Regulatory Affairs, Medical Devices, for Johnson Johnson, said President and CEO Martin Dieck. His disciplined and strategic approach to the product development and approval processes set him apart as a worldwide expert. We are thrilled to welcome him to Nfocus Neuromedical.

O'Holla has an extensive background in the fields of RD, quality, policy development and compliance, which uniquely position him for the dynamic needs of Nfocus and its next-generation endovascular devices. He chaired the Technology and Regulatory Advisory Committee at AdvaMed, a premier medical technology industry group for 13 years, and was a key figure in the construction of the Medical Device User Fee and Modernization Act of 2002, which amended and refined food and drug law related to medical devices.

I welcome the challenges and rewards of serving in my new role with Nfocus, noted O'Holla, as we strive to bring responsible and innovative products and technological solutions to the emerging field of endovascular neurosurgery.

About Nfocus Neuromedical, Inc.

Nfocus is positioning itself to be the world-wide leader in the development of next-generation endovascular neurosurgery solutions (surgery through less-invasive catheter devices). Backed by premier venture investors, the Company is developing revolutionary systems to treat neurovascular disease, including brain aneurysms, that are simple, safe, cost-effective and curative.

Nfocus was incubated at In-Cube Labs and is backed by Oxford Bioscience Partners, Technology Partners and DFJ-ePlanet Ventures. To learn more about the Nfocus Neuromedical development programs focused on providing faster, simpler and more permanent treatment of vascular diseases of the brain and spine, please visit the new Nfocus website at: www.nfocusneuro.com.

For more information about aneurysms and hemorrhagic stroke see: www.strokeassociation.org and www.snisonline.org

Martin S. Dieck, President and CEO, +1-650-845-3040, martin@nfocusneuro.com, or Thomas W. Ross, Vice President, +1-650-845-3042, tom@nfocusneuro.com, both of Nfocus Neuromedical, Inc.